Policy updates include:

• For initial approval criteria and continued therapy, added Attruby to list of excluded agents for concurrent use

Policy updates include:

• Updated to include withdrawal of previously Food and Drug Administration (FDA)-approved indication for urothelial cancer and changed to off-label as the use remains National Comprehensive Cancer Network (NCCN) supported
• Added provider attestation criterion acknowledging FDA withdrawal
• Added withdrawal information in Appendix D

Policy updates include:

• Added requirement for current documentation (within the last 90 days) of member’s body weight (in kg)

Policy updates include:

• Added newly Food and Drug Administration (FDA)-approved use in metastatic colorectal cancer in combination with cetuximab and mFOLFOX6.

Policy updates include:

• Added criteria for newly Food and Drug Administration (FDA)-approved indication of limited-stage small cell lung cancer

Policy updates include:

• Updated criteria to include new indication for gastric or gastroesophageal junction adenocarcinoma

Policy updates include:

• Added newly approved atopic dermatitis indication to criteria.

Policy updates include:

• Revised Xromi indication for pediatric extension up to 18 years of age

Policy updates include:•

• For Gemtesa added additional indication for overactive bladder in adult males on pharmacological therapy for benign prostatic hyperplasia per updated prescribing information.